Welcome, Guest. Please login or register.
November 22, 2017, 01:00:28 AM

Login with username, password and session length

  • Total Posts: 722635
  • Total Topics: 58730
  • Online Today: 310
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 2
Guests: 300
Total: 302


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Promising Study On Kaletra Monotherapy  (Read 3230 times)

0 Members and 1 Guest are viewing this topic.

Offline MitchMiller

  • Member
  • Posts: 564
Promising Study On Kaletra Monotherapy
« on: January 11, 2008, 10:28:57 PM »
I'm posting this study here because it is probably of most interest to those suffering from lipoatrophy.  Although, from what I've heard, Kaletra is not always a walk in the park, the is an opportunity to get away from NRTI's that are thought to cause lipoatrophy.  It was mentioned at the end of the article that this study is still considered too small and too short to recommend Kaletra monotherapy yet.

Here's the most important point... the results.  You can see the full story at www.natap.org.

At week 48, 94 of the 100 patients (94%) in the monotherapy group did not develop therapeutic failure compared to 88 of the 98 patients (90%) in the triple therapy group. The 95% CI for the difference between the two groups was -11.8 to 3.4% (P = 0.28), which fulfilled the pre-established criteria for non-inferiority of the monotherapy group. There were six therapeutic failures in the monotherapy group. Three were lost to follow-up. One changed randomized therapy without loss of virologic suppression. One lost virologic suppression and developed protease inhibitor resistance. One patient had loss of virologic suppression and then failed to maintain suppression after reinduction with baseline nucleosides. There were 10 therapeutic failures in the triple therapy group. Four were lost to follow up. Three had confirmed loss of virological suppression. Three discontinued randomized treatment due to adverse events. There were no significant statistical differences in the time to treatment failure between both groups by log-rank test (P = 0.29) (Fig. 2).
At week 48, six out of the 100 patients (6%) in the monotherapy group had developed confirmed loss of virological suppression compared to three out of 98 (3%) in the triple therapy group (P = 0.31). Of the six patients with loss of virological suppression in the monotherapy group, four resumed baseline nucleosides and regained virological suppression which was subsequently maintained for a median of 56 weeks (36-64). In one patient reinduction was not attempted per protocol, as genotypic testing showed lopinavir-ritonavir resistance and one patient did not maintain virological suppression after resuming baseline nucleosides.

Offline minismom

  • Member
  • Posts: 2,649
  • Quocumque jeceris stabit
Re: Promising Study On Kaletra Monotherapy
« Reply #1 on: January 12, 2008, 08:57:09 AM »
Do you know if further studies going to happen?  What I'm wondering, and the article doesn't say, is: how long the people in the study were undetectable before going to monotherapy, how old they were, how long they were infected before starting, and what measures were taken to guaruntee compliance.  This is a very interesting article indeed.  Hubby and I were just talking about "maintainance" dosages yesterday and wondering why no one had done a study.  Thank you for posting this.

"Whichever way you throw me, i will stand"
"Don't worry about the world coming to an end today...it's already tomorrow in Australia"  Charles Schultz

Offline MitchMiller

  • Member
  • Posts: 564
Re: Promising Study On Kaletra Monotherapy
« Reply #2 on: January 15, 2008, 11:07:15 PM »
I'm sure there will be more studies because this one was successful.  I have no doubt Abbott will be funding additional studies because this looks like it could prove to be a lucrative market for them.  The downside might be that PI monotherapy is also found to work for other PIs.  Good for us, bad for Abbott.


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.